- Home
- KLRS vs SNTI Comparison
KLRS vs SNTI Comparison
Compare KLRS & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- SNTI
- Stock Information
- Founded
- KLRS 2019
- SNTI 2016
- Country
- KLRS United States
- SNTI United States
- Employees
- KLRS N/A
- SNTI N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- SNTI Health Care
- Exchange
- KLRS Nasdaq
- SNTI Nasdaq
- Market Cap
- KLRS 46.0M
- SNTI 39.6M
- IPO Year
- KLRS N/A
- SNTI N/A
- Fundamental
- Price
- KLRS $6.46
- SNTI $1.82
- Analyst Decision
- KLRS Strong Buy
- SNTI Strong Buy
- Analyst Count
- KLRS 2
- SNTI 2
- Target Price
- KLRS $23.00
- SNTI $8.50
- AVG Volume (30 Days)
- KLRS 232.2K
- SNTI 139.1K
- Earning Date
- KLRS 11-15-2025
- SNTI 11-13-2025
- Dividend Yield
- KLRS N/A
- SNTI N/A
- EPS Growth
- KLRS N/A
- SNTI N/A
- EPS
- KLRS N/A
- SNTI N/A
- Revenue
- KLRS N/A
- SNTI N/A
- Revenue This Year
- KLRS N/A
- SNTI N/A
- Revenue Next Year
- KLRS N/A
- SNTI $150.00
- P/E Ratio
- KLRS N/A
- SNTI N/A
- Revenue Growth
- KLRS N/A
- SNTI N/A
- 52 Week Low
- KLRS $2.14
- SNTI $1.26
- 52 Week High
- KLRS $24.15
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- KLRS 59.57
- SNTI 76.79
- Support Level
- KLRS $6.50
- SNTI $1.36
- Resistance Level
- KLRS $8.80
- SNTI $1.43
- Average True Range (ATR)
- KLRS 0.95
- SNTI 0.09
- MACD
- KLRS 0.09
- SNTI 0.06
- Stochastic Oscillator
- KLRS 51.28
- SNTI 100.00
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.